-
-
-
In the News
Researchers discover four genetic subtypes of diffuse large B-cell...
“The genetic framework for DLBCL that we present here provides a new and evolving understanding of the pathogenesis of DLBCL and the molecular attributes that may influence therapeutic response,” they wrote in New England Journal of Medicine. “Unlike...
-
-
-
-
In the News
Impressive response with CAR T cells directed against CD19 for refractory...
In a study of 28 patients with lymphoma who received CTL019 cells, about 65% had a response—43% of patients with diffuse large B-cell lymphoma (DLBCL) and 71% of patients with follicular lymphoma (FL) achieved complete remission. One in three patients developed...
-
- Ibrutinib plus venetoclax: Dual therapy improves outcome in MCL In the News | July 12, 2018
- Exploring the impact of the diffuse large B-cell component in untreated follicular lymphoma In the News | May 25, 2018
- Minimal residual disease predicts relapse in AML In the News | April 24, 2018
- Responses maintained to 5 years with ponatinib in chronic-phase CML In the News | April 24, 2018
- Genetic subtypes identified in diffuse large B-cell lymphoma In the News | April 24, 2018
- New CLL regimen dramatically improved progression-free survival In the News | April 23, 2018
- TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens Cancer | September 11, 2017
- Benefits and barriers of newly approved CAR-T therapy for leukemia: A discussion with Dr. Elizabeth Jaffee Spotlight Interview | September 04, 2017
- Smoking and subsequent risk of acute myeloid leukaemia: A pooled analysis of 9 cohort studies in Japan Hematological Oncology | August 24, 2017